studies

la/mBC - HR-positive - 1st line (L1), abemaciclib based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsMONARCH 3, 2017 0.54 [0.41; 0.72] 0.54[0.41; 0.72]MONARCH 3, 201710%493NAnot evaluable CBRdetailed resultsMONARCH 3, 2017 1.42 [0.92; 2.17] 1.42[0.92; 2.17]MONARCH 3, 201710%493NAnot evaluable objective responses (ORR)detailed resultsMONARCH 3, 2017 1.76 [1.20; 2.59] 1.76[1.20; 2.59]MONARCH 3, 201710%493NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-10 16:26 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 716,1404,967,1443,1406,1338,1337

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons